nVerses Capital LLC Makes New Investment in LifeMD, Inc. (NASDAQ:LFMD)

nVerses Capital LLC acquired a new stake in shares of LifeMD, Inc. (NASDAQ:LFMD) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 8,700 shares of the company’s stock, valued at approximately $46,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in LifeMD by 12.5% during the first quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company’s stock worth $11,875,000 after buying an additional 128,701 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of LifeMD by 63.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 234,583 shares of the company’s stock worth $1,609,000 after acquiring an additional 91,183 shares during the period. Acadian Asset Management LLC boosted its position in shares of LifeMD by 261.8% during the 1st quarter. Acadian Asset Management LLC now owns 116,655 shares of the company’s stock valued at $1,198,000 after acquiring an additional 84,413 shares in the last quarter. X Square Capital LLC bought a new stake in LifeMD in the second quarter valued at about $509,000. Finally, Cubist Systematic Strategies LLC increased its stake in LifeMD by 15.1% in the second quarter. Cubist Systematic Strategies LLC now owns 551,344 shares of the company’s stock valued at $3,782,000 after acquiring an additional 72,203 shares during the period. 35.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. B. Riley assumed coverage on LifeMD in a report on Friday, August 23rd. They set a “buy” rating and a $11.00 price objective on the stock. KeyCorp decreased their price target on LifeMD from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $15.00 price objective on shares of LifeMD in a research note on Friday, September 20th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $12.00.

LifeMD Stock Down 1.6 %

Shares of LFMD opened at $4.42 on Wednesday. The company has a market capitalization of $184.57 million, a P/E ratio of -5.97 and a beta of 1.18. LifeMD, Inc. has a one year low of $4.10 and a one year high of $12.88. The business’s 50 day simple moving average is $5.02 and its 200-day simple moving average is $7.07. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.87 and a quick ratio of 0.83.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The business had revenue of $50.66 million during the quarter, compared to the consensus estimate of $48.47 million. During the same quarter in the prior year, the company posted ($0.23) earnings per share. As a group, sell-side analysts predict that LifeMD, Inc. will post -0.49 EPS for the current fiscal year.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.